{"id":"NCT05464420","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)","officialTitle":"A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-08-12","primaryCompletion":"2023-05-25","completion":"2023-05-25","firstPosted":"2022-07-19","resultsPosted":"2024-05-24","lastUpdate":"2024-09-24"},"enrollment":2162,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"V116","otherNames":["Pneumococcal 21-valent Conjugate Vaccine"]},{"type":"BIOLOGICAL","name":"PPSV23","otherNames":["PNEUMOVAX™23"]}],"arms":[{"label":"V116 Lot 1","type":"EXPERIMENTAL"},{"label":"V116 Lot 2","type":"EXPERIMENTAL"},{"label":"V116 Lot 3","type":"EXPERIMENTAL"},{"label":"PPSV23","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in pneumococcal vaccine-naïve adults 18 to 49 years of age.\n\nThe primary study hypothesis is that all 3 lots of V116 are equivalent as assessed by the serotype-specific opsonophagocytic activity (OPA) Geometric Mean Titers (GMTs) at 30 days postvaccination for all serotypes included in V116.","primaryOutcome":{"measure":"Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 Lots","timeFrame":"Up to 5 days","effectByArm":[{"arm":"V116 Lot 1","deltaMin":13.4,"sd":null},{"arm":"V116 Lot 2","deltaMin":14.2,"sd":null},{"arm":"V116 Lot 3","deltaMin":13.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":72,"countries":["United States","Austria","Canada","Denmark","Finland","Israel","Poland","Spain"]},"refs":{"pmids":["40543503"],"seeAlso":["https://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26086&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":539},"commonTop":["Injection site pain","Fatigue","Headache","Myalgia","Injection site erythema"]}}